Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Update on GSK's response to the Zika virus disease outbreak
Since the outbreak of Zika virus disease began in the Americas late last year, GSK has been assessing how we can best help to respond.
-
GSK ships 2016-17 seasonal influenza vaccines for US market
- First-to-market with quadrivalent vaccine - Company to deliver up to 40 million doses
-
FDA Approves FLONASE® Sensimist™ Allergy Relief
FDA Approves FLONASE® Sensimist™ Allergy Relief.
-
GSK unveils campaign to help prevent meningitis
Parents, young adults urged to educate themselves about meningitis B, responsible for one-third of U.S. cases
-
GSK announces $200,000 grant to East Durham Children’s Initiative
Kids lead the way to develop healthier lifestyles
-
GSK celebrates 20 years of a healthy and happy Philadelphia
Ten nonprofits will receive $40,000 to support youth sports, safety, housing, and other pressing community health needs
-
GSK supports a healthy and happy Triangle with $400,000
GSK IMPACT Award winners build healthy communities by addressing care of elders, homelessness, education and other pressing issues
-
GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older (1)
GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older (1)
-
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
-
GSK to divest Horlicks and other Consumer Healthcare nutrition products to Unilever
GSK to divest Horlicks and other Consumer Healthcare nutrition products to Unilever
-
GSK employees celebrate Giving Tuesday with awards to local nonprofits
GSK employees celebrate Giving Tuesday with awards to local nonprofits
-
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval
-
Access to Medicine Index 2018 media statement
Access to Medicine Index 2018 media statement
-
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma (1)
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
-
GSK announces $1 million grant to protect children in North Carolina, Puerto Rico from disaster
GSK announces $1 million grant to protect children in North Carolina, Puerto Rico from disaster
-
GSK awards Greater Philadelphia nonprofits making a dynamic IMPACT on health outcomes
GSK awards Greater Philadelphia nonprofits making a dynamic IMPACT on health outcomes
-
Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine
GSK today announced the publication of positive results from two phase III studies of single-dose tafenoquine
-
GSK announces succession plan to appoint new Chairman
GSK announces that Sir Philip Hampton has informed the Board of his intention to step down as non-executive Chairman
-
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GSK announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company
-
GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialize M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
GSK and Merck KGaA, Darmstadt, Germany today announced that they have entered into a global strategic alliance
